Danaher (DHR) Q2 2026 (USD): EPS 1.94 (exp. 1.84), Revenue 6.3bln (exp. 6.11bln)

Danaher's Q2 performance exceeded expectations with EPS of 1.94 vs.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Russian Deputy PM Novak says the fuel market has partially stabilised; situation remains difficult in some regions

US officials are reportedly preparing options to allow US President Trump to launch new tariffs of countries as soon as this week, the FT reports

Danaher (DHR) Q2 2026 (USD): EPS 1.94 (exp. 1.84), Revenue 6.3bln (exp. 6.11bln)

US and China are to hold AI talks in September, sources say

Newsquawk Daily US Opening News - 21st July 2026

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

Other Metrics (USD):

  • Diagnostics Revenue 2.47bln (exp. 2.34bln)
  • Life Sciences Revenue 1.88bln (exp. 1.8bln)
  • Biotech Revenue 1.92bln (exp. 1.96bln)

COMMENTARY:

  • CEO Rainer Blair says Danaher delivered a better-than-expected Q2, with core growth improving versus Q1 and disciplined execution driving high-single-digit adjusted EPS growth, while Life Sciences delivered its strongest quarter in several years and bioprocessing orders grew mid-teens.

GUIDANCE:

  • Sees Q3 core revenue growth between 2.0-3.0% Y/Y, and adj. operating profit margin of about 26.5%.
  • Raises FY26 guidance; sees FY adj. EPS between USD 8.45-8.60 (exp. 8.45; prev. saw saw 8.35-8.55)
Context

expected 1.84 and revenue of 6.3 billion vs. 6.11 billion. The CEO's commentary highlights strong growth in Life Sciences and better core performance, which could positively impact sentiment in the biotech and life sciences sectors, while the upgraded FY guidance reinforces confidence in the firm's growth trajectory.

Related headlines

The whole workspace, free to try.

Try it free